Insider Trading January 26, 2026

Cel-Sci CEO Acquires $200,000 in Stock; Board Signs Off on Shareholder Rights Agreement Revisions

Kersten Geert R. increased his stake while the company filed an exhibit to Form 8-K detailing governance updates without disclosing specifics

By Nina Shah CVM
Cel-Sci CEO Acquires $200,000 in Stock; Board Signs Off on Shareholder Rights Agreement Revisions
CVM

Cel-Sci Corp's chief executive, Kersten Geert R., bought 38,023 shares of the company's common stock on January 22, 2026, at $5.26 per share, a transaction totaling $200,000 that brings his direct ownership to 120,815 shares. Separately, the company's board approved revisions to its Shareholder Rights Agreement, disclosed as an exhibit to a Form 8-K, although the filing did not provide details of the changes. Cel-Sci's common stock remains listed on the NYSE American exchange.

Key Points

  • CEO Kersten Geert R. purchased 38,023 shares on January 22, 2026 at $5.26 per share, totaling $200,000.
  • After the purchase, Kersten directly holds 120,815 shares of Cel-Sci.
  • Cel-Sci's Board approved revisions to the Shareholder Rights Agreement and attached the updated agreement as an exhibit to a Form 8-K; the filing did not disclose the specifics. Sectors impacted include biotechnology, corporate governance, and capital markets.

Cel-Sci Corp reported a direct purchase of company shares by its chief executive officer, Kersten Geert R., according to a Form 4 filing with the Securities and Exchange Commission. On January 22, 2026, Kersten acquired 38,023 shares of common stock at a price of $5.26 per share. The filing records the total value of the transaction at $200,000. Following the purchase, Kersten's direct holdings in Cel-Sci total 120,815 shares.

In a related disclosure, Cel-Sci's Board of Directors approved revisions to the firm's Shareholder Rights Agreement. The company included the updated agreement as an exhibit to a Form 8-K filed with the SEC. The filing confirms the board action and the inclusion of the revised document but does not provide details about the substance of the changes made to the agreement.

Cel-Sci's common stock continues to trade on the NYSE American exchange. The company characterized the updates as part of ongoing corporate governance activity. The filings supply the factual record of both the insider purchase and the board's approval of amendments to the shareholder rights arrangement; the filings themselves do not elaborate on the intended effects or specific provisions altered by the board.

Below are the key takeaways from the filings and corporate disclosures:

  • Insider transaction: CEO Kersten Geert R. purchased 38,023 shares on January 22, 2026 at $5.26 per share, for a total of $200,000.
  • Post-transaction ownership: Kersten now directly owns 120,815 shares of Cel-Sci.
  • Governance update: The board approved revisions to the Shareholder Rights Agreement, and the revised agreement was attached as an exhibit to the company's Form 8-K; the filing does not describe the revisions.
  • Listing status: Cel-Sci's common stock remains listed on the NYSE American exchange.

These disclosures combine a routine insider acquisition with a governance filing. The Form 4 documents the CEO's purchase price and share count, while the Form 8-K records board action and the inclusion of the revised shareholder rights agreement as an exhibit. The filings establish the transactions and corporate actions but leave important details about the content of the governance changes unspecified.

Risks

  • The Form 8-K did not disclose the details of the Shareholder Rights Agreement revisions, creating uncertainty for investors about the nature and potential effects of those governance changes. This affects corporate governance and investor relations.
  • The filings document transactions and approvals but do not provide rationale or expected outcomes, leaving market participants with limited information to assess strategic implications. This introduces uncertainty for holders and potential investors in the biotech and capital markets sectors.

More from Insider Trading

Stifel Financial President Sells Small Stake, Exercises Options in Separate Transactions Feb 2, 2026 Corning Executive Sells $558,231 in Stock as Company Posts Slight Q4 Beat Feb 2, 2026 Mentor Capital CEO Makes Small Direct Purchases; Audit Firm Change Announced Feb 2, 2026 RENN Fund President Murray Stahl Purchases 1,154 Shares Valued at $2,971 Feb 2, 2026 Graco Director Disposes $1.25M in Stock After Exercising Options; Q4 Results Align with Expectations Feb 2, 2026